Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Baxter Healthcare Corporation has assumed exclusive rights to market and distribute Cangene Corporation's immune thrombocytopenic purpura treatment, WinRho SDF, in the US.
Subscribe to our email newsletter
WinRho SDF is used to treat immune thrombocytopenic purpura (ITP), a critical autoimmune bleeding disorder. Baxter currently markets WinRho SDF for Cangene in the UK and intends to launch the therapy in ten other European countries.
“Baxter’s knowledge and experience in distributing WinRho SDF in the UK, along with the company’s expertise in marketing bleeding disorder products in the US, make this partnership a good fit,” said Dr John Langstaff, president and CEO of Cangene.
ITP is caused by an abnormally low level of platelets. In ITP, the immune system produces antibodies against platelets causing their premature destruction. Individuals who suffer from ITP may have symptoms such as bruising on skin and gums, nosebleeds, or mucosal bleeding.
WinRho SDF is used to elevate the platelet level in patients with ITP. It is derived from human plasma and is administered intravenously.